Keythera Pharmaceuticals
Keythera Pharmaceuticals is a clinical-stage biopharmaceutical company founded on May 19, 2020, focusing on the development of innovative small molecule drugs for oncology and autoimmune diseases. The company leverages its proprietary Affinity Detection by Mass Spectroscopy (ADMS) platform for high-throughput drug screening, integrating bioinformatics, cheminformatics, structural chemistry, computer-aided drug design, and combinatorial chemistry. This platform, combined with AI, aims to accelerate drug discovery and reduce development risks. Their lead product, KF-0210, an EP4 receptor antagonist, is in Phase Ib clinical trials for solid tumors and has received NMPA approval for a Phase II clinical trial for osteoarthritis. Another product, KBP-2205, a novel oncology candidate, has completed PCC validation studies. The company's team comprises experienced professionals, with 86% in R&D, and a significant portion holding advanced degrees. Keythera Pharmaceuticals aims to be a leader in novel small molecule drug development in China and globally.
Keythera Pharmaceuticals
Keythera Pharmaceuticals is a clinical-stage biopharmaceutical company founded on May 19, 2020, focusing on the development of innovative small molecule drugs for oncology and autoimmune diseases. The company leverages its proprietary Affinity Detection by Mass Spectroscopy (ADMS) platform for high-throughput drug screening, integrating bioinformatics, cheminformatics, structural chemistry, computer-aided drug design, and combinatorial chemistry. This platform, combined with AI, aims to accelerate drug discovery and reduce development risks. Their lead product, KF-0210, an EP4 receptor antagonist, is in Phase Ib clinical trials for solid tumors and has received NMPA approval for a Phase II clinical trial for osteoarthritis. Another product, KBP-2205, a novel oncology candidate, has completed PCC validation studies. The company's team comprises experienced professionals, with 86% in R&D, and a significant portion holding advanced degrees. Keythera Pharmaceuticals aims to be a leader in novel small molecule drug development in China and globally.